

Joshua Brown, PharmD, PhD

Current Employment

2016 – present *Assistant Professor*
Department of Pharmaceutical Outcomes & Policy
University of Florida College of Pharmacy – Gainesville, FL

Education

2014 – 2016 *Ph.D. Pharmaceutical Outcomes & Policy*
University of Kentucky College of Pharmacy – Lexington, KY

2011 – 2014 *M.S. Pharmaceutical Evaluation & Policy*
University of Arkansas for Medical Science (UAMS)
College of Pharmacy – Little Rock, AR

2010 – 2014 *Pharm.D. Doctor of Pharmacy*
UAMS - College of Pharmacy – Little Rock, AR
With honors, with honors in research

2006 – 2010 *B.S. Biochemistry, Cum laude*
University of Arkansas – Fayetteville, AR

Former Employment

7/2014 – present *Humana-Pfizer Post-Doctoral Fellow*
Comprehensive Health Insights, Humana Inc. – Louisville, KY
Real World Data and Analytics, Outcomes & Evidence, Global
Health & Value, Pfizer Inc. – New York, NY
Supervisors: Margaret Pasquale, PhD; Jim Harnett, PharmD, MS;
Richard Willke, PhD; Marc Berger, PhD; Phil Schwab, PhD

Responsibilities: Served as a Research Consultant and project manager for collaborative research projects between Humana and Pfizer. Developed statements of work, project protocols and statistical analysis plans, and drafted final reports and manuscripts. Lead client and team meetings while completing tasks to manage project timelines. Presented study updates and findings to Joint Research Governance Committee and executive leadership. Served as epidemiological study design and pharmacy clinical expert on project team. Conducted internal research (Pfizer) for Market Access issues related to formulary status and evaluated advanced analytic solutions for automated systems.

Projects include (selected):

- **Burden of illness for community-acquired pneumonia.** Role: Lead Research Consultant
- **Payer and pharmaceutical manufacturer considerations for outcomes-based agreements and value-based insurance design.** Role: Research Consultant, lead for model development
- **Residual risk of cardiovascular events and LDL-C levels after treatment with moderate-to-high dose statins.** Role: Supporting Research Consultant
- **Conjoint analysis of patient preferences for treatments for psoriasis and psoriatic arthritis.** Role: Supporting Research Consultant.

- **Impact of preferred, equal, and disadvantaged formulary status on patient access to rheumatoid arthritis medications.** Role: Analyst

7/2014 – present Research Fellow

Institute for Pharmaceutical Outcomes & Policy – University of
Kentucky College of Pharmacy – Lexington, KY
Supervisor: Jeffery Talbert, PhD

Projects include:

- **Impact of low-cost generic programs on health plan quality measurement and research using administrative claims data.** Role: Study lead
- **Comparative effectiveness of oral anticoagulants for cancer-associated venous thromboembolism.** Role: Study lead
- **Evaluation of a multi-treatment propensity score technique for simultaneous comparison of ≥ 3 treatment groups.** Role: Study lead
- **Utilization patterns and comparative effectiveness of oral anticoagulants for atrial fibrillation.** Role: Study lead
- **Evaluation of treatment trends, effectiveness, and safety of vena cava filters for venous thromboembolism.** Role: Study lead
- **Access to opioid addiction treatment for pregnant women in Kentucky.** Role: Study lead
- **Risk of, and outcomes associated with, chronic opioid use in patients with Crohn's disease.** Role: Clinical SME, Co-investigator
- **Cash payments for opioid prescriptions among individuals with prescription drug insurance.** Role: Clinical SME, Co-investigator

Peer-reviewed Publications

1. Brown JD, Hutchison LC, Martin BC. Comparing the Tools to Identify Potentially Inappropriate Medications in the Elderly and Future Research Directions. *Journal of Gerontology and Geriatrics Research*. 2016. DOI: 10.4172/2167-7182.1000321.
2. Brown JD, Shewale AR, Dherange P, Talbert JC. Treatment with anticoagulants for stroke prevention in atrial fibrillation is increasing but further improvements are needed. *Journal of the American College of Cardiology*. 2016 (Accepted).
3. Brown JD, Pauly NJ, Doshi PA, Talbert JC. Neonatal Abstinence Syndrome (NAS) rates increase despite efforts to combat the opioid abuse epidemic. *JAMA Pediatrics*. 2016. doi:10.1001/jamapediatrics.2016.2150.
4. Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-naïve non-valvular atrial fibrillation. *J Manag care Spec Pharm*. 2016 Nov;22(11):1319-1329.
5. Brown JD and Talbert JC. Hospital variation and patient characteristics associated with vena cava filter utilization. *Medical Care*. 2016 (In press). DOI: 0.1097/MLR.0000000000000599
6. Brown JD, Sheer RL, Null KD, Pasquale MK, Sato R. The relative burden of community-acquired pneumonia in seniors. *American Journal of Preventive Medicine*. 2016. doi:10.1016/j.amepre.2016.05.015
7. Brown JD. Low-cost generic drug programs in the United States: implications for payers and researchers. *Generics and Biosimilars Initiative Journal*. 2016. DOI: 10.5639/gabij.2016.0501.003

8. Brown JD, Shewale AR, Dherange P, Talbert JC. Comparison of oral anticoagulant utilization for atrial fibrillation in the elderly in the post-DOAC era: therapeutic substitution or increased treatment? *Drugs & Aging*. 2016. DOI: 10.1007/s40266-016-0369-y
9. Brown JD, Talbert JC. Explained variation in hospital utilization of vena cava filters in Kentucky. *JAMA Surgery*. 2016. DOI: 10.1001/jamasurg.2016.1004
10. Brown JD, Pauly NJ, Talbert JC. The Prevalence and Predictors of Low-Cost Generic Program Use in a Nationally Representative Uninsured Population. *Pharmacy*. 2016;4(1):14. DOI: 10.3390/pharmacy4010014.
11. Brown J, Adams V. Incidence and Risk Factors of Thromboembolism with Multiple Myeloma in the Presence of Death as a Competing Risk: An Empirical Comparison of Statistical Methodologies. *Healthcare*. 2016;4(1):16. DOI:10.3390/healthcare4010016.
12. Brown JD, Doshi PA, Talbert JC. Utilization of free medication samples in the United States in a nationally representative sample: 2009-2013. *Res Social Adm Pharm*. January 2016. DOI:10.1016/j.sapharm.2016.01.006.
13. Brown JD, Hutchison LC, Li C, Painter JT, Martin BC. Predictive Validity of the Beers and Screening Tool of Older Persons' Potentially Inappropriate Prescriptions (STOPP) Criteria to Detect Adverse Drug Events, Hospitalizations, and Emergency Department Visits in the United States. *J Am Geriatr Soc*. 2016;64(1):22-30. doi:10.1111/jgs.13884.
14. Pauly NJ, Talbert JC, Brown JD. Low-Cost Generic Program Use By Medicare Beneficiaries: Implications For Medication Exposure Misclassification In Administrative Claims Data. *J Manag care Spec Pharm*. 2016;22(6):741-751. DOI:10.18553/jmcp.2016.22.6.741
15. Pauly NJ, Brown JD. Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults. *J Manag care Spec Pharm*. 2015;21(12):1162-1170. doi:10.18553/jmcp.2015.21.12.1162.
16. Brown JD, Ratermann K, Talbert J, Adams V. Competing Risks Analysis of Cancer-associated Recurrent Thrombosis, Major Bleeds, and Death in a Geriatric Cohort. *JHEOR*. 2015;3(2):214-223.
17. Pauly NJ, Talbert JC, Brown JD. The Prevalence and Predictors of Low-Cost Generic Program Use in the Pediatric Population. *Drugs - Real World Outcomes*. 2015;2(4):411-419. doi:10.1007/s40801-015-0051-4.
18. Shewale AR, Borse MS, Brown JD, Li C. Mental health status of varenicline and bupropion users during a quit attempt compared to current smokers, other quitters, and non-smokers. *Drug Alcohol Depend*. 2015;154:132-138. doi:10.1016/j.drugalcdep.2015.06.028.
19. Brown J, Li C. Characteristics of online pharmacy users in a nationally representative sample. *J Am Pharm Assoc*. 2014;54(3):289-294. doi:10.1331/JAPhA.2014.13169.
20. Gupta PK, Brown J, Biju PG, et al. Development of high-throughput HILIC-MS/MS methodology for plasma citrulline determination in multiple species. *Anal Methods*. 2011;3(8):1759. doi:10.1039/c1ay05213f.

Manuscripts in draft

1. Schwab P, Brown J, et al. Residual risk of high LDL-C levels after treatment with moderate-to-high statins.
2. Brown JD, et al. Statin use and risk of cancer-associated venous and arterial thromboembolic events and overall survival
3. Pasquale MK, Sheer RS, Brown JD, et al. Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements and Value-Based Insurance Designs

Selected Poster and Podium Abstracts

1. Brown JD, Talbert JC. Variation in the use of vena cava filters in Kentucky hospitals. International Conference for Pharmacoepidemiology, Dublin, IRL, August 23-27, 2016.
2. Brown JD, Adams VR, Moga DM. Transient impact of treatment exposures and one-year incidence of thrombosis in multiple myeloma: a case-time-control analysis. ISTH SSC Meeting, Montpellier, FR, May 22-25, 2016. *Podium and poster **Young Investigator Award ***Top Abstract Award ****Presidential Award
3. Brown J, Pauly N, Talbert J. The Prevalence and Predictors of Low-Cost Generic Program Use in the Pediatric Population. AMCP Annual Meeting, San Francisco, CA, April 19-22, 2016. *Gold Medal Abstract Award
4. Brown J, Sheer R, Null K, Pasquale M, Sato R. The relative burden of community-acquired pneumonia hospitalizations compared to other serious conditions in the older population. AMCP Annual Meeting, San Francisco, CA, April 19-22, 2016. *Silver Medal Abstract Award
5. Brown JD, Adams VR, Moga DM. Transient impact of treatment exposures and one-year incidence of thrombosis in multiple myeloma: a case-time-control analysis. ICPE Mid-Year Conference, Baltimore, MD, April 10-12, 2016. *Podium **Abstract scholarship award
6. Brown J, MacLean E, Cisar L, Mardekian J, Harnett J. Treatment patterns and costs associated with axitinib and everolimus treatment for renal cell carcinoma: a commercial health claims analysis. American Society of Clinical Oncology (Accepted).
7. Pauly NJ, Brown JD. Low-Cost Generic Program Use By Medicare Beneficiaries: Implications For Medication Exposure Misclassification In Administrative Claims Data. International Conference for Pharmacoepidemiology (ICPE), Boston, MA, August 22-26, 2015
8. Pauly NJ, Brown JD. Use of low-cost generic programs in a nationally representative Medicare population and implications for quality initiatives. ISPOR International Meeting, Philadelphia, PA, May 16-20, 2015. AMCP Annual Meeting, San Francisco, CA. *Gold Medal Abstract Award
9. Pauly NJ, Brown JD. Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Medicare Beneficiaries. ISPOR International Meeting, Philadelphia, PA, May 16-20, 2015.
10. Brown J, Ratermann K, Talbert J, Adams V. Risk of recurrent VTE or bleed in cancer patients: a time-to-event analysis. Hematology/Oncology Pharmacy Association Annual Conference, 2015, Austin, TX, March 25-28.
11. Brown J, Ratermann K, Talbert J, Adams V. Factors directing anticoagulation treatment in cancer patients with VTE. UHC Pharmacy Council Meeting, Anaheim, CA, December 5-6, 2014.

Grants and research support

- “Cancer-related venous thromboembolism: treatment choice, patterns, and outcomes.”
 - Role: Co-PI. Submitted in partnership with faculty mentors. Funded (\$40,000) by the Hematology-Oncology Pharmacist Association (HOPA, 2016).

Honors and awards

- Gold medal abstract, Academy of Managed Care Pharmacy Annual Meeting (2016)
- Silver medal abstract, Academy of Managed Care Pharmacy Annual Meeting (2016)
- Best Graduate Student Poster, Rho Chi Research Day, University of Kentucky College of Pharmacy (2016)
- Young Investigator Award, International Society for Thrombosis and Haemostasis (2016)

- Milwaukee Presidential ISTH Scientific and Standardization Committee Award (2016)
- Top Abstract Award, ISTH Scientific and Standardization Committee Meeting (2016)
- Student Travel Award, ISPE Annual Conference (2016)
- Student Abstract Award, ISPE Mid-Year Meeting (2016)
- University of Kentucky Graduate Student Travel Award (2015, 2016)
- Student Travel Award for European Congress, International Society for Pharmacoeconomics and Outcomes Research European Congress (2014)
- Paul Ambrose Scholars Program (2013)
- AACP-Walmart Scholars Program (2013)
- Express Scripts Dual Degree Scholar (2012-14)

Professional membership

- International Society on Thrombosis and Haemostasis (Member)
- International Society for Pharmacoepidemiology (Member)
- American Geriatrics Society (Member)
- Academy of Managed Care Pharmacy (Member)
- Association for Prevention Teaching and Research (Member and Scholar)
- Rho Chi Pharmacy Honor Society (Member and Student Officer)
- International Society for Pharmacoeconomics and Outcomes Research (Member and Student Officer)
- Kappa Psi Pharmaceutical Fraternity (Member, Student Officer, National Officer)